MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of projects currently in development for the prevention and treatment of Human Immunodeficiency Virus (HIV).
Respiratory syncytial virus (RSV) is a virus that causes respiratory infections affecting mainly young children, the elderly and immunocompromised individuals. It can cause serious infections of the upper and lower respiratory tracts.
The human immunodeficiency virus (HIV) remains a major public health issue worldwide. According to UNAIDS, around 39 million people were living with HIV in 2022, and almost 1.3 million new infections were recorded that year. Thanks to advances in antiretroviral (ARV) treatment, the AIDS mortality rate has fallen sharply, from 1.7 million in 2004 to around 630,000 in 2022. However, access to treatment remains uneven across the world, with significant disparities in sub-Saharan Africa, where the majority of cases are concentrated.
Epidemiological data
1,3 M
people were newly infected worldwide in 2023
39,9 M
people living with HIV worldwide in 2023
630 000
people died of HIV-related illnesses worldwide in 2023
PIPELINE
Significant advances have been made in HIV research, thanks in particular to the emergence of new biotherapeutic approaches. There are currently 249 biologics in development in the active pipeline.
Among these, broadly targeted neutralising antibodies (bNAbs) are attracting growing interest. These molecules, which are capable of recognising and neutralising various strains of HIV, are currently being tested in combination with ARVs to boost the efficacy of treatment and reduce the frequency with which drugs are taken.
249
biologics under development
Development phases
Focus on Proteins and Antibodies
Gene therapy is also a promising avenue, with strategies aimed at modifying the genome of immune cells to make them resistant to infection. Clinical trials are exploring the use of CRISPR-Cas9 technology to eliminate HIV from infected cells.
Finally, therapeutic vaccines, which aim to stimulate the immune system to better control the virus, are also being developed. Although preliminary results are encouraging, their effectiveness has yet to be confirmed on a larger scale. At the same time, efforts are also being made to develop prophylactic vaccines to prevent HIV infection. Several candidates are in clinical trials, including those using messenger RNA technology, already proven in the fight against COVID-19. However, because of the genetic variability of the virus and its ability to evade the immune system, this research still faces major challenges.
Focus on vaccines
Focus on Cell and Gene Therapies
Biologics therefore offer exciting prospects in the fight against HIV, although challenges remain, particularly in terms of the cost, accessibility and durability of treatments. Research continues to explore these avenues with the aim of improving the quality of life of people living with HIV and, ultimately, achieving a functional or complete cure.
Want to find out more?
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources : MabDesign & GlobalData
Date – May 2025
